Education
About Us
Working with TipRanks
Follow Us
IQVIA Holdings (IQV)
:IQV
IQV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$134.65 - $252.88
Previous CloseN/A
Volume300.39K
Average Volume (3M)2.14M
Market Cap
$31.02B
Enterprise Value$40.81B
Total Cash (Recent Filing)$2.19B
Total Debt (Recent Filing)$15.70B
Price to Earnings (P/E)26.4
Beta0.95
Next Earnings
Oct 22, 2025EPS Estimate
2.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.81
Shares Outstanding170,000,000
10 Day Avg. Volume2,951,902
30 Day Avg. Volume2,136,672
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue2.60
Enterprise Value/Gross Profit7.59
Enterprise Value/Ebitda12.15
Forecast
1Y Price Target
$211.67Price Target Upside15.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Market PositionIQV's best-in-class clinical health network and AI-empowered data-driven solutions should enable the company to outpace the market and win share.
Revenue GrowthThe company's total revenue growth exceeded expectations, showing strong performance in TAS and R&DS segments.
Bears Say
Margin CompressionMargins compressed year-over-year, largely due to an increase in FSP services and PTs in R&DS as well as revenue mix.
Pricing PressureIQV is facing some pricing pressures to stay competitive and win contracts with customers, especially among emerging biopharma.
IQVIA Holdings News
IQV FAQ
What was IQVIA Holdings’s price range in the past 12 months?
IQVIA Holdings lowest stock price was $134.65 and its highest was $252.88 in the past 12 months.
What is IQVIA Holdings’s market cap?
IQVIA Holdings’s market cap is $31.02B.
When is IQVIA Holdings’s upcoming earnings report date?
IQVIA Holdings’s upcoming earnings report date is Oct 22, 2025 which is in 76 days.
How were IQVIA Holdings’s earnings last quarter?
IQVIA Holdings released its earnings results on Jul 22, 2025. The company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.771 by $0.039.
Is IQVIA Holdings overvalued?
According to Wall Street analysts IQVIA Holdings’s price is currently Undervalued.
Does IQVIA Holdings pay dividends?
IQVIA Holdings does not currently pay dividends.
What is IQVIA Holdings’s EPS estimate?
IQVIA Holdings’s EPS estimate is 2.98.
How many shares outstanding does IQVIA Holdings have?
IQVIA Holdings has 170,000,000 shares outstanding.
What happened to IQVIA Holdings’s price movement after its last earnings report?
IQVIA Holdings reported an EPS of $2.81 in its last earnings report, beating expectations of $2.771. Following the earnings report the stock price went up 17.879%.
Which hedge fund is a major shareholder of IQVIA Holdings?
Currently, no hedge funds are holding shares in IQV
IQVIA Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$211.67 (15.08% Upside)
$211.67 (15.08% Upside)
Blogger Sentiment
Bullish
IQV Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 190.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.27%
12-Months-Change
Fundamentals
Return on Equity
19.80%
Trailing 12-Months
Asset Growth
8.46%
Trailing 12-Months
Company Description
IQVIA Holdings
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IQV Company Deck
IQV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with record revenue and strategic achievements in AI and TAS. However, challenges such as market uncertainty, gross margin compression, and pricing pressures were noted. The positive aspects slightly outweigh the negatives, showing a resilient business despite external pressures.View all IQV earnings summariesIQV Revenue Breakdown
55.35% Research & Development Solutions
39.99% Technology & Analytics Solutions
4.66% Contract Sales & Medical Solutions
IQV Stock 12 Month Forecast
Average Price Target
$211.67
▲(15.08% Upside)
Technical Analysis
Ownership Overview
0.87% Insiders
24.48% Mutual Funds
1.39% Other Institutional Investors
46.93% Public Companies and
Individual Investors